



ABN 53 075 582 740

**ASX ANNOUNCEMENT
3 August 2015**

BIONOMICS STRENGTHENS MANAGEMENT TEAM WITH APPOINTMENT OF TONY COLASIN AS U.S.-BASED CHIEF BUSINESS OFFICER

Bionomics Limited (ASX:BNO), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced the appointment of Tony Colasin as Chief Business Officer. Based in San Diego, California, Mr. Colasin will lead corporate development including business development and strategic opportunities.

"We are delighted to welcome Tony to the Bionomics team. His operational experience in our core therapeutic areas – CNS and oncology – as well as his ability to execute on business development activities will be critical as we continue to advance our clinical programs and expand our U.S. presence," said Deborah Rathjen, Chief Executive Officer and Managing Director of Bionomics.

Mr. Colasin brings over 20 years of experience in senior business development, product commercialization, and corporate finance roles at major biopharmaceutical companies, contributing to the success of key brands including EPOGEN® and Cialis. He joins Bionomics from Ironwood Pharmaceuticals, where he served as Vice President of Corporate Development and was responsible for strategy and tactical oversight of in-licensing, and mergers and acquisitions. Previously he was Senior Director of Business Development for ICOS Corporation for six years and before that, he held positions at Amgen in various marketing, corporate finance and corporate development roles. Mr. Colasin holds a B.S. from the University of Southern California and a M.B.A. from the Anderson School of Management at the University of California, Los Angeles. Mr. Colasin also served in the U.S. Marine Corps.

"I am very much looking forward to working with the Bionomics team to grow the company and its strategic footprint in the U.S. and worldwide," commented Mr. Colasin. "I see tremendous opportunity for both our CNS and cancer pipelines, especially our lead programs BNC210 for anxiety and depression, and BNC101 targeting cancer stem cells."

FOR FURTHER INFORMATION PLEASE CONTACT:

Australia
Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US
Stern IR, Inc.
Beth Del Giacco
+1 212 362 1200
beth@sternir.com

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumors. BNC101 is expected to enter a Phase 1 clinical trial in the fourth quarter of 2015. Bionomics also has strategic partnerships with Merck & Co. in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This presentation contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.